Benjamin T. Dake - Jul 31, 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Jul 31, 2024
Transactions value $
$22,552
Form type
4
Date filed
8/2/2024, 06:00 PM
Previous filing
Apr 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $19.9K +11.5K +887.22% $1.74 12.7K Jul 31, 2024 Direct
transaction AVTE Common Stock Options Exercise $2.62K +1.51K +11.82% $1.74 14.3K Aug 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -906 -100% $0.00* 0 Jul 31, 2024 Common Stock 906 $1.74 Direct F1
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -10.5K -87.5% $0.00 1.51K Jul 31, 2024 Common Stock 10.5K $1.74 Direct F2
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -1.51K -100% $0.00* 0 Aug 1, 2024 Common Stock 1.51K $1.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary